Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Subscribe To Our Newsletter & Stay Updated